XML 27 R18.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENT INFORMATION
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
SEGMENT INFORMATION

NOTE 9 — SEGMENT INFORMATION

 

The Company views its operations and manages its business as one operating and reportable segment, which is the business of designing and developing innovative neurostimulation products. The Company’s focus centers around the treatment of various mental health conditions without the need for drugs or psychotherapy. Consistent with the operational structure, the Chief Executive Officer, as the chief operating decision maker (“CODM”), manages and allocates resources on a consolidated basis. This decision-making process reflects the way in which the financial information is regularly reviewed and used by the CODM to evaluate performance, set operational targets, forecast future financial results, and allocate resources.

 

The Company’s CODM assesses financial performance and allocates resources based on consolidated net loss that also is reported on the consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the consolidated balance sheets as total consolidated assets. The CODM utilizes consolidated net loss by comparing actual results against budgeted amounts on a quarterly basis. As part of this process, consolidated net loss is a critical performance measure used to evaluate the Company’s operating performance and guide strategic decisions and resource allocations, including additional investments in research and development and commercialization activities.

 

The following table provides information about the Company’s one reportable segment and includes the reconciliation to consolidated net loss.

 

               
    Three Months Ended
March 31,		  
    2025     2024  
Total revenues   $ 41,015     $ 78,671  
Less:                
Cost of revenues (excluding amortization and depreciation)     13,558       9,156  
Research and development expense (excluding share-based compensation expense):                
Clinical trials     79,402       1,238  
Halo Project     298,037       103,477  
Desktop project     23,713       -  
Other research and development     5,136       953  
General and administrative expense (excluding stock based compensation and amortization expense)     622,948       645,719  
Amortization     4,786       2,662  
Stock-based compensation     636,844       161,349  
Professional fees     367,816       227,829  
Interest income, net     (1,103 )     (304 )
Equity in net (income) loss from equity method investees     1,048       (5,783 )
Other income     (22,833 )     (26,468 )
Segment net loss     (1,988,337 )     (1,041,157 )
                 
Reconciliation of net loss                
Adjustments and reconciling items     -       -  
Consolidated net loss   $ (1,988,337 )   $ (1,041,157 )